Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan.
JAMA Pediatr. 2021 Jul 1;175(7):723-729. doi: 10.1001/jamapediatrics.2021.0433.
The adverse effects from the long-term use of oral corticosteroids are known, but, to our knowledge, few studies have reported the risk of corticosteroid bursts, particularly among children.
To quantify the associations of corticosteroid bursts with severe adverse events, including gastrointestinal (GI) bleeding, sepsis, pneumonia, and glaucoma, in children.
DESIGN, SETTING, AND PARTICIPANTS: This study used data derived from the National Health Insurance Research Database in Taiwan from January 1, 2013, to December 31, 2017, on children younger than 18 years of age and used a self-controlled case series design. Data were analyzed from January 1 to July 30, 2020.
Oral corticosteroid bursts (defined as oral corticosteroid use for ≤14 days).
Incidence rates were calculated of 4 severe adverse events (GI bleeding, sepsis, pneumonia, and glaucoma) in children who did or did not receive corticosteroid bursts. Conditional fixed-effect Poisson regression was used to estimate incidence rate ratios (IRRs) of severe adverse events within 5 to 30 days and 31 to 90 days after initiation of corticosteroid bursts.
Among 4 542 623 children, 23% (1 064 587; 544 268 boys [51.1%]; mean [SD] age, 9.7 [5.8] years) were prescribed a single corticosteroid burst. The most common indications were acute respiratory tract infections and allergic diseases. The incidence rate differences per 1000 person-years between children administered a single corticosteroid burst and those not prescribed corticosteroids were 0.60 (95% CI, 0.55-0.64) for GI bleeding, 0.03 (95% CI, 0.02-0.05) for sepsis, 9.35 (95% CI, 9.19-9.51) for pneumonia, and 0.01 (95% CI, 0.01-0.03) for glaucoma. The IRRs within 5 to 30 days after initiating corticosteroid bursts were 1.41 (95% CI, 1.27-1.57) for GI bleeding, 2.02 (95% CI, 1.55-2.64) for sepsis, 2.19 (95% CI, 2.13-2.25) for pneumonia, and 0.98 (95% CI, 0.85-1.13) for glaucoma; the IRRs within the subsequent 31 to 90 days were 1.10 (95% CI, 1.02-1.19) for GI bleeding, 1.08 (95% CI, 0.88-1.32) for sepsis, 1.09 (95% CI, 1.07-1.11) for pneumonia, and 0.95 (95% CI, 0.85-1.06) for glaucoma.
This study suggests that corticosteroid bursts, which are commonly prescribed for children with respiratory and allergic conditions, are associated with a 1.4- to 2.2-fold increased risk of GI bleeding, sepsis, and pneumonia within the first month after initiation of corticosteroid therapy that is attenuated during the subsequent 31 to 90 days.
长期使用口服皮质类固醇的不良反应是已知的,但据我们所知,很少有研究报告皮质类固醇爆发的风险,特别是在儿童中。
定量评估皮质类固醇爆发与严重不良事件(包括胃肠道出血、败血症、肺炎和青光眼)之间的关联,这些事件在儿童中发生。
设计、地点和参与者:本研究使用了来自台湾国家健康保险研究数据库 2013 年 1 月 1 日至 2017 年 12 月 31 日的数据,涉及年龄在 18 岁以下的儿童,采用了自身对照病例系列设计。数据分析于 2020 年 1 月 1 日至 7 月 30 日进行。
口服皮质类固醇爆发(定义为口服皮质类固醇使用 ≤14 天)。
计算了在接受或未接受皮质类固醇爆发的儿童中发生 4 种严重不良事件(胃肠道出血、败血症、肺炎和青光眼)的发生率。使用条件固定效应泊松回归估计皮质类固醇爆发后 5 至 30 天和 31 至 90 天内严重不良事件的发生率比(IRR)。
在 4542623 名儿童中,23%(1064587 人;544268 名男孩[51.1%];平均[SD]年龄为 9.7[5.8]岁)接受了单次皮质类固醇爆发治疗。最常见的指征是急性呼吸道感染和过敏疾病。在接受单次皮质类固醇爆发治疗和未接受皮质类固醇治疗的儿童中,每 1000 人年的发病率差异分别为胃肠道出血 0.60(95%CI,0.55-0.64)、败血症 0.03(95%CI,0.02-0.05)、肺炎 9.35(95%CI,9.19-9.51)和青光眼 0.01(95%CI,0.01-0.03)。皮质类固醇爆发后 5 至 30 天内的 IRR 分别为胃肠道出血 1.41(95%CI,1.27-1.57)、败血症 2.02(95%CI,1.55-2.64)、肺炎 2.19(95%CI,2.13-2.25)和青光眼 0.98(95%CI,0.85-1.13);随后 31 至 90 天内的 IRR 分别为胃肠道出血 1.10(95%CI,1.02-1.19)、败血症 1.08(95%CI,0.88-1.32)、肺炎 1.09(95%CI,1.07-1.11)和青光眼 0.95(95%CI,0.85-1.06)。
本研究表明,皮质类固醇爆发在儿童中常用于治疗呼吸道和过敏疾病,与皮质类固醇治疗开始后第一个月内胃肠道出血、败血症和肺炎的风险增加 1.4-2.2 倍相关,这种风险在随后的 31-90 天内减弱。